The long-term management of pancreas transplantation

Martin Mai, Nasimul Ahsan, Thomas Gonwa

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Diabetes mellitus (DM) is a major health problem worldwide, which affects 18.2 million individuals (6.3% of the population) in the United States. Currently, the prevalence of Type 1 DM in the United States is estimated to be 1,000,000 individuals, and 30,000 new cases are diagnosed each year. In addition to end-stage renal disease (ESRD), DM is associated with blindness, accelerated atherosclerosis, dyslipidemia, cardio- and cerebrovascular disease, amputation, poor quality of life, and overall lifespan reduction. It accounts for more than 160,000 deaths per year in the United States alone. In 2002, the annual national direct and indirect costs of Types 1 and 2 DM exceeded $130 billion, which included hospital and physician care, laboratory tests, pharmaceutical products, and patient workdays lost because of disability or premature death. Hyperglycemia alone or in concert with hypertension is the primary factor influencing the development of major diabetic complications. From 1990 to 2001, the number of existing ESRD cases to DM increased by more than 300%, while the rate per million populations increased from 167% to 491%. The number is expected to grow 10-fold by 2030 to 1.3 million accounting for 60% of ESRD population. To date, DM is the leading indication for transplantation and is the cause of ESRD in more than 40% of all transplant recipients each year.

Original languageEnglish (US)
Pages (from-to)991-1003
Number of pages13
JournalTransplantation
Volume82
Issue number8
DOIs
StatePublished - Oct 2006

Fingerprint

Pancreas Transplantation
Chronic Kidney Failure
Diabetes Mellitus
Type 1 Diabetes Mellitus
Population
Cerebrovascular Disorders
Premature Mortality
Diabetes Complications
Blindness
Dyslipidemias
Amputation
Hyperglycemia
Type 2 Diabetes Mellitus
Atherosclerosis
Cardiovascular Diseases
Transplantation
Quality of Life
Hypertension
Physicians
Costs and Cost Analysis

Keywords

  • Complications
  • Management
  • Pancreas transplant
  • Survival

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

The long-term management of pancreas transplantation. / Mai, Martin; Ahsan, Nasimul; Gonwa, Thomas.

In: Transplantation, Vol. 82, No. 8, 10.2006, p. 991-1003.

Research output: Contribution to journalArticle

Mai, Martin ; Ahsan, Nasimul ; Gonwa, Thomas. / The long-term management of pancreas transplantation. In: Transplantation. 2006 ; Vol. 82, No. 8. pp. 991-1003.
@article{cf9d3bf922774401892b279c6ac29f63,
title = "The long-term management of pancreas transplantation",
abstract = "Diabetes mellitus (DM) is a major health problem worldwide, which affects 18.2 million individuals (6.3{\%} of the population) in the United States. Currently, the prevalence of Type 1 DM in the United States is estimated to be 1,000,000 individuals, and 30,000 new cases are diagnosed each year. In addition to end-stage renal disease (ESRD), DM is associated with blindness, accelerated atherosclerosis, dyslipidemia, cardio- and cerebrovascular disease, amputation, poor quality of life, and overall lifespan reduction. It accounts for more than 160,000 deaths per year in the United States alone. In 2002, the annual national direct and indirect costs of Types 1 and 2 DM exceeded $130 billion, which included hospital and physician care, laboratory tests, pharmaceutical products, and patient workdays lost because of disability or premature death. Hyperglycemia alone or in concert with hypertension is the primary factor influencing the development of major diabetic complications. From 1990 to 2001, the number of existing ESRD cases to DM increased by more than 300{\%}, while the rate per million populations increased from 167{\%} to 491{\%}. The number is expected to grow 10-fold by 2030 to 1.3 million accounting for 60{\%} of ESRD population. To date, DM is the leading indication for transplantation and is the cause of ESRD in more than 40{\%} of all transplant recipients each year.",
keywords = "Complications, Management, Pancreas transplant, Survival",
author = "Martin Mai and Nasimul Ahsan and Thomas Gonwa",
year = "2006",
month = "10",
doi = "10.1097/01.tp.0000238666.60361.3d",
language = "English (US)",
volume = "82",
pages = "991--1003",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - The long-term management of pancreas transplantation

AU - Mai, Martin

AU - Ahsan, Nasimul

AU - Gonwa, Thomas

PY - 2006/10

Y1 - 2006/10

N2 - Diabetes mellitus (DM) is a major health problem worldwide, which affects 18.2 million individuals (6.3% of the population) in the United States. Currently, the prevalence of Type 1 DM in the United States is estimated to be 1,000,000 individuals, and 30,000 new cases are diagnosed each year. In addition to end-stage renal disease (ESRD), DM is associated with blindness, accelerated atherosclerosis, dyslipidemia, cardio- and cerebrovascular disease, amputation, poor quality of life, and overall lifespan reduction. It accounts for more than 160,000 deaths per year in the United States alone. In 2002, the annual national direct and indirect costs of Types 1 and 2 DM exceeded $130 billion, which included hospital and physician care, laboratory tests, pharmaceutical products, and patient workdays lost because of disability or premature death. Hyperglycemia alone or in concert with hypertension is the primary factor influencing the development of major diabetic complications. From 1990 to 2001, the number of existing ESRD cases to DM increased by more than 300%, while the rate per million populations increased from 167% to 491%. The number is expected to grow 10-fold by 2030 to 1.3 million accounting for 60% of ESRD population. To date, DM is the leading indication for transplantation and is the cause of ESRD in more than 40% of all transplant recipients each year.

AB - Diabetes mellitus (DM) is a major health problem worldwide, which affects 18.2 million individuals (6.3% of the population) in the United States. Currently, the prevalence of Type 1 DM in the United States is estimated to be 1,000,000 individuals, and 30,000 new cases are diagnosed each year. In addition to end-stage renal disease (ESRD), DM is associated with blindness, accelerated atherosclerosis, dyslipidemia, cardio- and cerebrovascular disease, amputation, poor quality of life, and overall lifespan reduction. It accounts for more than 160,000 deaths per year in the United States alone. In 2002, the annual national direct and indirect costs of Types 1 and 2 DM exceeded $130 billion, which included hospital and physician care, laboratory tests, pharmaceutical products, and patient workdays lost because of disability or premature death. Hyperglycemia alone or in concert with hypertension is the primary factor influencing the development of major diabetic complications. From 1990 to 2001, the number of existing ESRD cases to DM increased by more than 300%, while the rate per million populations increased from 167% to 491%. The number is expected to grow 10-fold by 2030 to 1.3 million accounting for 60% of ESRD population. To date, DM is the leading indication for transplantation and is the cause of ESRD in more than 40% of all transplant recipients each year.

KW - Complications

KW - Management

KW - Pancreas transplant

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33750338301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750338301&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000238666.60361.3d

DO - 10.1097/01.tp.0000238666.60361.3d

M3 - Article

VL - 82

SP - 991

EP - 1003

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 8

ER -